STING1 and cancer: The preferential stimulation of STING/TBK1/IRF3 pathway in BRCA1-defective tumors has been confirmed by further in vivo studies [99], speaking in favor of a prediction for greater intra-tumor T cell penetration in BRCA1-defective cancers and of a more modest effect of combined therapy in tumors with a proficient HR system [86].